Pioneering Strategies to Unlocking the Potential of KRAS

Once labeled “undruggable,” KRAS has emerged as one of oncology’s most promising—yet complex—targets. With nearly 90% of pancreatic cancers and 30-40% of lung and colorectal cancers harboring KRAS mutations, the need for effective therapies is urgent. Recent FDA approvals of KRAS G12C inhibitors have signaled a new era, but the rise of resistance and diverse mutation profiles demand deeper innovation. As preclinical tools and combination strategies evolve, scientists must ask: how do we stay ahead of KRAS-driven resistance and translate insights into patient-specific treatment success?

So, what will it take to overcome the final barriers to fully unlocking the therapeutic potential of KRAS?

In this episode of CrownCast, host Jonny McMichael, VP of Client Experience & Enablement at Crown BioScience, is joined by Dr. Rajendra Kumari, Executive Director of Integrated Solutions. Together, they delve into KRAS biology, resistance mechanisms, and preclinical strategies reshaping drug discovery. Their conversation touches on cutting-edge translational modeling and what the future holds for combination therapies targeting KRAS mutations.

Key topics covered in this episode:

  • Why KRAS mutations are uniquely challenging—and how recent breakthroughs have shifted the “undruggable” narrative.

  • The rise of G12C inhibitors and how resistance is reshaping combination strategies in colorectal and lung cancer.

  • The essential role of preclinical models, including engineered systems and PDXs, in predicting clinical response and guiding next-gen drug development.

Dr. Rajendra Kumari brings over two decades of oncology research experience to Crown BioScience. A PhD in pharmacology from the University of Leicester, Jen co-founded preclinical CRO PreCOS in 2010, which was acquired by Crown in 2013. She has held various leadership roles including CSO, COO, and GM of Crown UK, and now leads global integrated solutions, driving innovation in translational modeling and oncology strategy.

Recent Episodes

In this episode of Care Anywhere: The Global Health Workforce Podcast, host Lea Sims welcomes Syl Trepanier, DNP, RN, Chief Nursing Officer for Providence Health and member of the TruMerit Board of Trustees. With responsibility for representing more than 36,000 nurses across a multi-state health system, Syl shares his personal journey from caregiving as…

The accelerator model is undergoing a transformation, and at the center of this change is HealthTech Arkansas, a powerful program that’s redefining the traditional approach by guaranteeing clinical pilots for healthcare startups. As the healthcare system faces a mounting burden from chronic disease (cardiovascular-related costs alone are projected to reach a staggering $1.8 trillion…

Michael Rothman explores the complexities of sepsis identification and management, highlighting the challenges posed by varying definitions and clinical pathways. He discusses the ineffectiveness of current sepsis screening protocols, which often yield high false-positive rates and fail to reduce mortality meaningfully. The episode concludes by questioning the focus on sepsis-specific initiatives and suggesting that more…